Form 4: Schrodinger Executive Robert Lorne Abel Reports Stock Option Grant

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., reported the grant of stock options on March 21, 2024.

Summary

• Robert Lorne Abel, an executive at Schrodinger, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Abel on March 21, 2024.
• Abel received options to purchase 30,000 shares of Schrodinger's common stock at an exercise price of $27.51 per share.
• The options vest with respect to 25% of the shares on March 4, 2025, and the remainder vest in equal monthly installments through March 4, 2028.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Stock option grants are a common form of executive compensation in the technology and pharmaceutical industries, often used to align management's interests with those of shareholders and incentivize long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the tech and biotech sectors.
• The vesting schedule described (25% after one year, then monthly) is a fairly typical vesting arrangement.
• Comparing the size of the grant (30,000 shares) to similar companies would require analyzing Schrodinger's compensation policies and the executive's role within the company.

Stakeholder Impact

• The stock option grant could incentivize Robert Lorne Abel to contribute to the long-term success of Schrodinger, potentially benefiting shareholders.
• The grant does not have an immediate impact on employees, customers, suppliers, or creditors.

Key Dates